Adicet Bio (NASDAQ:ACET – Get Free Report) is expected to post its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect Adicet Bio to post earnings of ($0.36) per share for the quarter.
Adicet Bio (NASDAQ:ACET – Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.05. On average, analysts expect Adicet Bio to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Adicet Bio Price Performance
Shares of ACET stock opened at $0.78 on Monday. The firm has a 50-day moving average of $0.91 and a 200-day moving average of $1.12. The company has a market cap of $64.71 million, a P/E ratio of -0.46 and a beta of 1.97. Adicet Bio has a one year low of $0.74 and a one year high of $2.43.
Analysts Set New Price Targets
Check Out Our Latest Analysis on ACET
Adicet Bio Company Profile
Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
See Also
- Five stocks we like better than Adicet Bio
- Quiet Period Expirations Explained
- How to Build the Ultimate Everything ETF Portfolio
- Earnings Per Share Calculator: How to Calculate EPS
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Russell 2000 Index, How Investors Use it For Profitable Trading
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.